AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05661721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sweet licorice
Description: Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
Study NCT05661721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Salty licorice
Description: A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
Study NCT05313750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-infective therapy sitafloxacin
Description: anti-infective therapy
Study NCT05313750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-infective therapy levofloxacin
Description: anti-infective therapy
Study NCT05741099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells implantation
Description: Patient in Mscs group will receive MSCs implantation by intravenous injection.
Study NCT05741099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparator
Description: Patients in comparator group will receive placebo treatment
Study NCT06310902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Single-cell Sequencing Analysis
Description: Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.
Study NCT04503096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-dose accelerated rTMS
Description: A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized. All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span. A single session = 600 pulses at 120% resting motor threshold (rMT), intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex. Total pulses = 14,400. To enable adherence and retention, the days do not need to be contiguous. Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
Study NCT04935918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACT
Description: Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck. The ACT system is a permanent implant designed for the correction of incontinence in patients.
Study NCT05923398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention Group
Description: Participants will use a Digital Intervention Suite composed of a virtual reality (VR) scenario, a web-based platform, and a wearable device to assess their stress response in near-real time and in a hypothetical stressful scenario.~During the VR scenario, physiological signals such as Galvanic Skin Response (GSR), Electrocardiogram (ECG), Respiratory Independence (RI), and Photoplethysmography will be measured. Additionally, an educational intervention video on how to deal with stress and distress will be shown to participants. We will then request participants to practice the skills taught during the intervention video in the VR scenario.~The wearable device (Oura Ring) will measure sleep, activity, readiness information, heart rate, heart rate variability, body temperature (delta), and respiratory rate. Additionally, the web-based platform will, through questionnaires, assess stress-related symptoms such as loneliness, anxiety, depression, and moral injury.
Study NCT06262945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnoses
Description: All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
Study NCT06262945 — intervention group
Intervention type: PROCEDURE
Intervention: traditional osteotomies
Description: In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
Study NCT06262945 — intervention group
Intervention type: BIOLOGICAL
Intervention: platelet rich fibrin
Description: Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
Study NCT06262945 — intervention group
Intervention type: DRUG
Intervention: Antibiotics, Penicillin
Description: Antibiotics are prescribed for the patients.
Study NCT06262945 — intervention group
Intervention type: DEVICE
Intervention: low laser therapy, bicure laser
Description: There are studies in the literature that low-energy lasers have positive effects on the biological and biochemical processes of wound healing. Acceleration of local circulation, increase in cell proliferation and collagen synthesis are among the various effects of laser application. B Cure Dental Pro Laser application will be applied to the patient for the first 3 days. Low dose laser application will be applied to the angulus area, covering the surgical area for 8 minutes. Before this laser procedure, the patient will be asked to fill out a pain scale. This pain scale and the number of analgesics used will be monitored for 3 days.
Study NCT06262945 — intervention group
Intervention type: DRUG
Intervention: Analgesic
Description: Analgesics are prescribed for the patients.
Study NCT05811039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remo-Wax® Oil
Description: Remo-Wax® Oil (abbreviated RWO; GMDN (Global Medical Device Nomenclature) code 46259, Earwax softening oil), is a CE-marked, non-sterile fluid mixture, used for prevention of impacted earwax. Remo-Wax® Oil also moisturizes the skin in the ear canal and reduces itching and irritation caused by the ear canal dryness
Study NCT06450717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Khymeia VRRS
Description: VRRS is an electronic device for remote rehabilitation of cognitive (e.g., memory, attention, spatial perception, logical-mathematical skills, language, executive functions...) and motor (gross and fine motor skills) functions. It can be used in on-line and off-line mode at home, and the exercises are chosen by the therapist according to the patient's specific difficulties and needs from a cognitive and motor library.
Study NCT05224635 — intervention group
Intervention type: PROCEDURE
Intervention: Vascular Injury
Description: The Society of Vascular Surgery has established a robust vascular disease registry but this organization's focus is on vascular disease and lacks capture of the data points necessary to discern trauma-specific outcomes. Recent military experience from the United States and United Kingdom, including the Balad Vascular Registry and the Global War on Terror (GWOT) Vascular Registry have provided a contemporary assessment of wartime vascular injury, but again these studies have been retrospective case series and registry reviews. Furthermore, applications of lessons learned in wartime vascular injury do not completely translate to management in trauma centers in the United States.
Study NCT06130579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-Α
Description: Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
Study NCT05303090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: H101 intratumorally injection starts at day 0.
Study NCT05303090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study NCT01095900 — intervention group
Intervention type: PROCEDURE
Intervention: conservative lateral internal sphincterotomy
Study NCT01095900 — intervention group
Intervention type: PROCEDURE
Intervention: Intra-sphincteric Botulinum-toxin injection
Study NCT05437861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: A short conversation with the participant regarding their use of opioids will be conducted. During the conversation the participants potential drug dependency will be uncovered. Further the pros and cons of weaning of the medication will be explained and a new treatment plan will be proposed.
Study NCT04774237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIMOCHOL™
Description: A single drop in each eye at a visit.
Study NCT04774237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIMOCHOL™ F
Description: A single drop in each eye at a visit.
Study NCT04774237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbachol
Description: A single drop in each eye at a visit.
Study NCT05404256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
Description: Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
Study NCT05404256 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radical gastrectomy +D2 lymphadenectomy
Description: Radical gastrectomy +D2 lymphadenectomy
Study NCT05421702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic conventional colectomy
Description: Laparoscopic colectomy with only lymph node dissection up to level 2 lymph nodes D2.
Study NCT05421702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic complete mesocolic excision
Description: Laparoscopic colectomy with lymphovascular dissection from level 3 lymph nodes or more D3.
Study NCT05315206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: The patient will be given 10 ml of Citicoline oral solution (Neurotidine ®) once a day in the morning for 1 year. To patients will be given 4 bottles containing 500 ml of Citicoline and the relative instructions for administration. After 6 months, the patient will bring back the used bottles and will be given additional 4 bottles containing Citicoline (Neurotidine ®). Again at the end of this 6 month period the patient will bring back the used bottles.~Each bottle of Neurotidine will contain: water; fructose; Citicoline (500 mg per 10 ml); acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavine.
Study NCT05315206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will be given 10 ml of an oral solution of Placebo. Each bottle of Placebo, the solution of which will be indistinguishable from the active product in terms of appearance and flavor, will contain: water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavin
Study NCT06327503 — intervention group
Intervention type: OTHER
Intervention: saliva samples collecting
Description: non-invasive collection of unstimulated whole saliva by spitting method into sterile plastic container
Study NCT06277869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Jacket
Description: In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention Thermal Jacket as well as Kangaroo Mother Care.
Study NCT06277869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Mother Care
Description: Skin-to-Skin care, provided by primary caregiver.
Study NCT06277869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Description: Skin-to-Skin care, provided by primary caregiver.
Study NCT05482373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleuropein from olive tree
Description: The capsules intake will last for a total of 4 months.
Study NCT05482373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsules intake will last for a total of 4 months.
Study NCT05097092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic immobilization
Description: Orthopedic immobilization will be performed with a sling and swathe.
Study NCT05097092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training
Description: Unilateral resistance training will be performed by the dominant arm of the immobilization + unilateral resistance training group during Phase 1.
Study NCT05097092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral resistance training
Description: Bilateral resistance training will be performed by both arms in both groups during Phase 2.
Study NCT06337916 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Stabilization Exercise
Description: The cervical stabilization exercise group will receive cervical stabilization exercises 1 session a day, 3 days a week for 6 weeks. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
Study NCT06337916 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Standard Exercise Group
Description: The patients in cervical standard exercise group will receive conventional cervical exercise for 6 weeks, 3 days a week, 1 session a day. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
Study NCT04786223 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: C-11 ER-176
Description: Participants will receive a one-time administration of C-11 ER176 and undergo a PET/CT imaging study. Blood samples for plasma biomarker testing will be obtained as part of the study.
Study NCT04786223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood Test
Description: Participants will undergo a one time venipuncture blood collection to evaluate the presence of inflammatory and genetic markers.
Study NCT06124755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viabahn endoprosthesis group
Description: Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
Study NCT06124755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated balloon group
Description: Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
Study NCT06484348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of eating behaviors
Description: Overall eating behaviors will be assessed from pictures of consumed food and drinks taken by the participants with their smartphones. A complete assessment of eating habits will be carried out daily for 4 days. For each photo, the participants will indicate the reasons why they ate by completing analogical scales (hunger, craving, sleepiness, stress, negative emotion) and an open question (other reason). These data will be used to determine the reason and timing of food intake and the number of calories ingested for each food category. Eating behaviors specifically related to sugar intake will be monitored using the FREESTYLE PRO® sensor. This small device is used routinely for diabetes care and is placed on the back of the arm. The system is designed to measure glucose levels in the interstitial fluid every 15 minutes for up to 14 days. The recorded data can be downloaded by an investigator using the FREESTYLE LIBRE PRO® reader.
Study NCT06484348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring of eating behaviors
Description: Overall eating behaviors will be assessed from pictures of consumed food and drinks taken by the participants with their smartphones. A complete assessment of eating habits will be carried out daily for 4 days. For each photo, the participants will indicate the reasons why they ate by completing analogical scales (hunger, craving, sleepiness, stress, negative emotion) and an open question (other reason). These data will be used to determine the reason and timing of food intake and the number of calories ingested for each food category. Eating behaviors specifically related to sugar intake will be monitored using the FREESTYLE PRO® sensor. This small device is used routinely for diabetes care and is placed on the back of the arm. The system is designed to measure glucose levels in the interstitial fluid every 15 minutes for up to 14 days. The recorded data can be downloaded by an investigator using the FREESTYLE LIBRE PRO® reader.
Study NCT06484348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of sleep/wake rhythm
Description: The sleep-wake rhythm will be measured continuously during the 5 days, both subjectively (sleep diary) and objectively, using the GT9X LINK ACTIGRAPH.
Study NCT06484348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring of sleep/wake rhythm
Description: The sleep-wake rhythm will be measured continuously during the 5 days, both subjectively (sleep diary) and objectively, using the GT9X LINK ACTIGRAPH.
Study NCT06484348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measure of nocturnal sleep parameters
Description: The quality and quantity of the participants' sleep will be recorded using the SOMFIT® device. This non-invasive portable device will allow the determination of sleep architecture as well as sleep EEG microstructure.
Study NCT06484348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measure of nocturnal sleep parameters
Description: The quality and quantity of the participants' sleep will be recorded using the SOMFIT® device. This non-invasive portable device will allow the determination of sleep architecture as well as sleep EEG microstructure.
Study NCT06484348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measure of sleepiness
Description: Sleepiness will be assessed by the Karolinska Sleepiness Scale (KSS) at the initiation of food intake and 30 min and 2 hours afterwards, and by analysis of EEG activity recorded by the SOMFIT® over a time window surrounding food intake. Indeed, participants will also be asked to wear the device as much as possible during the day when they are at home in order to explore sleepiness markers during wakefulness.
Study NCT06484348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measure of sleepiness
Description: Sleepiness will be assessed by the Karolinska Sleepiness Scale (KSS) at the initiation of food intake and 30 min and 2 hours afterwards, and by analysis of EEG activity recorded by the SOMFIT® over a time window surrounding food intake. Indeed, participants will also be asked to wear the device as much as possible during the day when they are at home in order to explore sleepiness markers during wakefulness.
Study NCT05118230 — intervention group
Intervention type: OTHER
Intervention: Inclisiran
Description: Prospective observational study. There is no treatment allocation. Chinese Patients who receive inclisiran in authorized health institutions are eligible to enroll into this study.
Study NCT05303090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study NCT05923229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Walking Therapy (MBWT)
Description: MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.
Study NCT05923229 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Freezing of Gait (FOG) Education
Description: Participants will receive materials to read weekly about FOG and track their usual care regimens.